In the News

199 News Items found
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Feature
Top Cancer Treatment Advances at MSK in 2022
Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
A researcher pipettes in the lab
New MSK research helped develop a machine-learning tool to help find cancer cells that remain after surgery; led to FDA approval for CAR T cell therapy against mantle cell lymphoma; tested a liquid biopsy approach that shows promise in detecting lung cancer; found checkpoint inhibitors were effective against endometrial and ovarian cancers with DNA-repair deficiency; and shed new light on mTOR's role in metabolic enzyme degradation.
Pictured: Cancer cell on blood vessel
In the Lab
Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there.
Genetic counselor Elise Fiala and pediatric cancer expert Michael Walsh
Finding
The largest study of its kind to look at data from children with cancer finds inherited cancer genes are more common than expected.
Dr. Bob Li
Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.
Blood vessels supply tumors with the nutrients they need to grow.
Decoder
What Is Angiogenesis?
Cancer biologist Robert Benezra explains angiogenesis, the process by which new blood vessels form, and how it relates to cancer research.
Staff involved in implementing the new technology for diagnosing gene mutations in tumors include (from left) Marc Ladanyi, Angela Marchetti, Chris Lau, Laetitia Borsu, and Khedoudja Nafa.
Memorial Sloan Kettering has made an important step forward in efficiently diagnosing gene mutations in patients' cancers on an individual basis.
Meryl Jacobs poses with her husband and grandkids
The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator.
MSK colon cancer patient Derrick Edwin wearing triathlon medals stands with his wife AnnaMarie
Learn more about how MSK is helping a new generation of patients — including triathlete Derrick Edwin — to navigate work and careers while undergoing treatment for cancer.
three tobacco hornworm caterpillars held in a scientist's hand
How scientists are working to develop nonmammalian alternatives that could reduce the number of rodents used in biomedical research.